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Alzheimer’s disease (AD) is a disease caused by the complex interaction of multiple mechanisms, some of which are still not fully
understood. To date, pharmacological treatments and supplementation of individual nutrients have been poorly effective in terms
of the prevention and treatment of AD, while alternative strategies based on multimodal approaches (diet, exercise, and cognitive
training) seem to be more promising. In this context, the focus on dietary patterns rather than on single food components could be
more useful in preventing or counteracting the pathological processes typical of AD, thanks to the potential synergistic effects of
various nutrients (neuronutrients). The aim of this narrative review is to summarize the currently existing preclinical and
clinical evidence regarding the Mediterranean diet (MeDi), the Dietary Approaches to Stop Hypertension (DASH) diet, and the
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, which are three dietary patterns with well-
known anti-inflammatory and antioxidant properties. Recently, they have been related to brain protection and AD prevention,
perhaps thanks to their high content of neuroprotective bioactive compounds. Similarly, intermittent fasting (IF) or calorie
restriction (CR) is emerging as interesting approaches that seem to promote hippocampal neurogenesis, activate adaptive stress
response systems, and enhance neuronal plasticity, thus leading to motor and cognitive improvements in animal models of AD
and hopefully also in human beings.
1. Introduction
Alzheimer’s disease (AD) is a disease of later life, affecting
one in four people 85 years of age or over, and the inci-
dence is expected to rise in the coming years, with 131.5
million estimated cases by 2050 [1]. To date, approved
drugs have shown modest clinical benefits in delaying the
neurodegenerative process, and currently, the AD epidemic
is facing two major challenges. Both the lack of disease
modifying drugs and the need to delay cognitive-related
disability and frailty trajectories highlight the necessity to
develop nonpharmacological strategies to stop this ever-
increasing global burden. In line with this, previous studies,
including the milestone Rotterdam study, have pointed out
the relevance of nutrition in counteracting brain neurode-
generation [2].
Although several nutritional approaches have been con-
sidered as possible alternatives to the currently existing drugs
for AD, this line of research has only been partially explored
and has not resulted in any solid evidence [3, 4].
The neuropathology and etiology of AD indicate that
a complex series of molecular mechanisms is involved,
including the amyloid hypothesis, mitochondrial dysfunc-
tion, oxidative stress, and brain neuroinflammation as the
mainstream molecular pathways [5]. In turn, the neuroin-
flammatory cascade may be synergistically associated with
immunosenescence and gut dysbiosis, intercepting the
trajectories of the aging brain and the progression to
dementia [6].
Recent evidence has indicated that epigenetics could help
shed light on such a complex neurodegenerative pattern.
DNA methylation, histone modifications, and microRNAs
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2019, Article ID 9874159, 20 pages
https://doi.org/10.1155/2019/9874159
are the principal epigenetic mechanisms involved in AD
pathophysiology. In line with this, nutrition is believed to
be a modifiable environmental factor that seems to strongly
impact on AD pathology by modulating its phenotypic
expression [7, 8].
Therefore, recent literature reports have underlined the
protective role of a number of individual food components,
including micro- and macronutrients in the prevention and
management of AD [9, 10]. Several researchers have explored
the role of single food components, as well as lifestyle habits
and inappropriate diets in facilitating the development of AD
and its clinical progression. By virtue of the role of cardiovas-
cular risk factors in the onset of AD [11], nutritional
approaches targeting insulin resistance, dyslipidemia, and
oxidative stress have been found to ameliorate the related
clinical conditions, such as diabetes, metabolic syndrome,
and dyslipidemia [12–14].
In keeping with the understanding of the complex inter-
play between nutrition and AD, a multinutrient approach
has also been developed which is based on the rationale
that multiple dietary molecules can interact in a synergistic
manner to modulate several AD molecular hallmarks.
Namely, omega-3 fatty acids, vitamin B and E, choline,
and uridine have provided the rationale for improving
effectiveness in AD prevention and clinical management.
However, to date, no clinical evidence that this putative
nutritional supplementation prevents AD onset or progres-
sion has been reported [15]. Based on the current findings,
it is unlikely that a single food component or a multinutrient
supplementation actually represents the right way to prevent
the development of AD or slow down its progression.
However, the interactions among several individual
nutrients seem to provide the ground for effectiveness with
respect to dementia prevention in older adults.
Another important aspect is that all the theoretical evi-
dence that has been collected so far shows a series of pitfalls
that hamper practical concepts and the clinical transferability
of results.
The main limitations that prevent bench to bedside
translation may be related to the experimental conditions
and the pharmacological concentrations of the specific food
components that hardly mimic human dietary intake and
daily recommended doses. Although animal studies seem to
be promising, few and contradictory results have been
observed in human trials [16]. Moreover, the heterogeneity
of the study designs and the paucity of large scale clinical epi-
demiological and observational studies on the causal link
between nutrition and AD make the results even more diffi-
cult to understand.
Besides these issues, strategies that focus on dietary
patterns rather than on an approach based on individual
foods or nutrients seem to provide a unifying conceptual
framework between nutrition and AD; the various compo-
nents or “neuronutrients” included in a good dietary pat-
tern can offer potential synergistic and neuroprotective
effects [16–18].
Adopting this as our starting point, our review will sum-
marize the latest developments regarding the use of dietary
patterns in older adults as a way to prevent AD.
Thus, studies whose outcomes include “cognitive func-
tions” or “global cognitive performance” or the incidence of
a generic “cognitive decline” or “cognitive impairment” will
not be taken into consideration.
2. Mediterranean Diet (MeDi) and
AD Prevention
The Mediterranean diet (MeDi) would appear to be promis-
ing for AD prevention, including the earlier predementia
stages. Indeed, the MeDi diet, based on traditional eating
habits in Greece, Southern Italy, and other Mediterranean
regions, albeit with regional differences, is characterized by
high consumption of fruits and vegetables, cereals, legumes,
olive oil, nuts, and seeds as the major source of fats, moderate
consumption of fish, low to moderate consumption of dairy
products and alcohol (wine), and low intake of red and
processed meats (see Table 1). It can be considered a
nutritional model for healthy dietary habits since it con-
tains all the essential nutrients including monounsaturated
fatty acids (mainly in olive oil), polyunsaturated fatty acids
(in fatty fish), antioxidants (e.g., allium sulphur compounds,
anthocyanins, beta-carotene-flavonoids, catechins, caroten-
oids, indoles, or lutein), vitamins (A, B1, 6, 9, 12, D, and E),
and minerals (magnesium, potassium, calcium, iodine, zinc,
and selenium) [19]. Growing evidence indicates the neuro-
protective potential of the MeDi, thus supporting the ratio-
nale that adherence to this dietary pattern can be a
preventative approach towards reducing the risk of cognitive
decline, mild cognitive impairment (MCI), and AD [20, 21].
2.1. Epidemiological Evidence (See Table 2). Two cross-
sectional studies [22, 23] showed an inverse correlation
between the Mediterranean diet and AD in older American
and Australian adults. In the first study [22], which was per-
formed on a cohort of elderly American subjects living in
New York, the MeDi score (which is a 9-point scale devel-
oped on the basis of the eating habits of a Greek population,
with higher scores indicating greater adherence) was the
main predictor of AD status in logistic regression models
adjusted for potential confounders for both AD (age, sex, eth-
nicity, education, apolipoprotein E genotype, caloric intake,
smoking, medical comorbidity index, and body mass index)
and for vascular risk factors (dyslipidemia, hypertension,
and coronary heart disease) that should be considered possi-
ble mediators in the pathogenesis of AD. Higher adherence
to the MeDi was associated with a significantly lower risk of
AD, considering MeDi adherence both as a continuous and
a categorical variable [24]. In the second cross-sectional
study, Gardener et al. [23] replicated these results in an Aus-
tralian population of older adults participating in the Austra-
lian Imaging, Biomarkers and Lifestyle Study of Ageing
(AIBL) study. As compared to healthy controls, subjects with
a diagnosis of MCI or AD had a lower mean MeDi score, and
every 1-unit increase in the MeDi score was associated with a
19–26% decrease in the odds of being in the AD category.
Several prospective studies have been published in the
last 15 years examining the role of the MeDi diet in reducing
the risk of dementia and AD. Numerous US population-
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based studies having a median follow-up of 3–5.4 years
revealed that greater adherence to the MeDi was associated
with a reduced risk of AD [25–28], a lower risk of developing
AD in patients with MCI [29], and lower mortality in AD
patients, suggesting a possible role of MeDi in modulating
not only the pathogenetic pathways but also the subsequent
course of AD [30]. A more recent longitudinal study
conducted in a Greek population as part of the Hellenic Lon-
gitudinal Investigation of Ageing and Diet (HELIAD) [31]
evaluated adherence to the MeDi pattern using a more com-
plicated score, i.e., the Mediterranean Dietary Score (Med-
DietScore) [32]. The authors of the HELIAD study found
that each unit increase in the MedDietScore was associated
with a 10% decrease in the odds of dementia.
Unlike the previously mentioned studies, three other
prospective studies found no association. In a French study,
MeDi adherence was not associated with a risk of incident
dementia or AD as a continuous or as a categorical variable
[33]. In another study, Roberts et al. reported a 25%
reduced risk of MCI or dementia in subjects in the upper
tertile of the MeDi score at baseline, but this association
did not reach statistical significance, possibly due to the rel-
atively short follow-up (median follow − up = 2 2 years)
[34]. In the third one, Olsson et al. found no correlation
between MeDi adherence and the risk of AD or all-type
dementia in a cohort of 1,138 elderly Swedish men
followed-up for 12 years [35].
Several systematic reviews and meta-analyses of both
case-control and longitudinal studies confirmed the associa-
tion between higher adherence to MeDi and a reduced risk
of stroke, depression, and neurodegenerative diseases (cogni-
tive decline, dementia, MCI, AD, and Parkinson’s disease),
albeit with some contradictory results [36–41]. Several fac-
tors can at least partly explain these differences in results.
The first one is the use of different methods for evaluating
eating habits (0 to 9 score, 0 to 55 score, and others): these
scores are usually validated in a specific population having
specific characteristics, eating habits, and culture. Therefore,
they cannot easily be applied to other populations, especially
non-Mediterranean ones, such as the Americans or Austra-
lians. As already discussed with regard to the assessment of
MeDi adherence, the two most commonly used scores are
the Trichopoulou’s 0 to 9 score [24] and the Panagiotakos’s
0 to 55 score [32]. The use of these two scoring systems has
been extensively reported in the literature and both have
proven to be reliable and valid tools for assessing adherence
to theMediterranean diet, but they are both based on the typ-
ical eating habits of the Greek population, so it is difficult to
apply these scores to non-Mediterranean populations. More-
over, there is broad heterogeneity in the study characteristics,
Table 1: Type and frequency of consumption of foods of the various dietary patterns having a role in AD prevention.
Dietary pattern
Characteristics
Moderate-to-high consumption Low consumption
Mediterranean diet (MeDi)
Whole-grain cereals (1-2 s every main meal)
Vegetables (≥2 s/every main meal)
Fruits (1-2 s/every main meal)
Olive oil (every main meal)
Olives/nuts/seeds (1-2 s/every day)
Low-fat diaries (2 s/every day)
Herbs/spices/garlic/onions (every day)
Eggs (2-4 s/week)
White meat (2 s/week)
Fish/seafood (≥2 s/week)
Potatoes (≤3 s/week)
Legumes (≥2 s/week)
(Red) wine
Added salt
Red meat (<2 s/week)
Processed meat (<1 s/week)
Sweets (≤2 s/week)
Dietary Approaches to Stop
Hypertension (DASH)
Whole-grain products (every day)
Vegetables (every day)
Fruits (every day)
Diary (moderate-to-high consumption)
Poultry (2 s/week)
Fish/seafood (1-2 s/week)
Legumes (2 s/week)
Saturated fats
Total fats
Salt (sodium)
Sweetened beverages
Red and processed meats
Mediterranean-DASH Intervention for
Neurodegenerative Delay (MIND)
Green leafy vegetables (≥6 s/week)
Other vegetables (≥1 s/day)
Nuts (≥5 s/week)
Berries (≥2 s/week)
Beans (≥3 s/week)
Whole grains (≥3 s/day)
Fish (≥1 s/week)
Poultry (≥2 s/week)
Olive oil (primary oil used)
(Red) wine (1 glass/day)
Red meats (<4 s/week)
Butter and stick margarines
Cheese (<1 s/week)
Pastries and sweets (<5 s/week)
Fried or fast food (<1 s/week)
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such as the mean age of subjects, the duration of follow-up,
and the high number of neuropsychological tests used for
the diagnosis of MCI and/or AD.
2.2. Randomized Controlled Trials (RCTs). Only few RCTs
(PREDIMED, MedLey, and NU-AGE) have assessed the
effects of a Mediterranean dietary pattern on cognition in
older adults both in Mediterranean and non-Mediterranean
countries (see Table 2).
The first RCT to evaluate the effects of long-term MeDi
intervention on cognitive function and to shed some light
on the role of dietary patterns in counteracting the neurode-
generative process was carried out on a subcohort of the well-
known multicenter PREDIMED trial, which was a milestone
in establishing the strong preventive role of the MeDi in indi-
viduals at a high cardiovascular risk [42]. The nutritional
intervention of PREDIMED consisted in a typical MeDi
supplemented with extravirgin olive oil or mixed nuts (foods
with antioxidant and anti-inflammatory properties) com-
pared to a control low-fat diet. Martinez-Lapiscina and col-
leagues [43] enrolled 522 subjects and assessed the overall
cognitive performance at study completion alone, after 6.5
years. They reported a significant difference in mean Mini-
Mental State Examination (MMSE) and Clock Drawing Test
(CDT) scores in both intervention groups versus the low-fat
control group. There were two main limitations in this study:
(1) the lack of evaluation of cognitive performance at the
beginning of the study, which did not allow to evaluate
changes in cognitive functions over time and (2) the insuffi-
cient statistical power to demonstrate a protective effect of
MeDi on dementia development, given the small number of
total incident cases that were observed during the follow-up.
After a few years, Valls-Pedret et al. [44] published the
first MeDi intervention trial demonstrating a positive effect
on cognition of the MeDi supplemented with either nuts or
extravirgin olive oil. In this PREDIMED substudy, cognitive
performance was evaluated both pre- and postintervention,
thus enabling the researchers to detect any significant cogni-
tive improvement in the participants allocated to the MeDi
intervention groups, who were assessed after a median of
4.1 years.
The MedLey study was the first RCT conducted in older
non-Mediterranean adults. A total of 137 subjects were ran-
domly assigned to either a MeDi or a control diet (their usual
diet) for six months. This study did not find any significant
beneficial effects of a MeDi intervention on cognitive func-
tions (executive functioning, speed of processing, memory
visual-spatial ability, and overall age-related cognitive perfor-
mance) among healthy older adults, perhaps because of the
short duration of the intervention, the relatively limited
number of participants, or the “Australianization” of the
MeDi (i.e., based on the Australian foods and habits, rather
than on the traditional MeDi), resulting in smaller nutri-
tional intervention differences between the intervention
groups and the control group [45].
The NU-AGE trial (NCT01754012), a recent 1-year mul-
ticenter RCT, was carried out in both Mediterranean (includ-
ing Italy) and non-Mediterranean European countries and
allocated a total of 1,279 healthy older adults to two parallel
groups. The intervention group followed the NU-AGE
diet, which consisted of a culturally adapted and individu-
ally tailored Mediterranean-like diet on the basis of the
specific dietary recommendations for older adults in the
various countries involved in the study. One year later,
at the end of the study, all participants showed improve-
ments in their cognitive performance but the differences
between the two groups did not reach statistical significance
[46]. Nonetheless, the authors highlighted that the partici-
pants in the intervention group with the highest adherence
to the NU-AGE diet showed a significant improvement in
episodic memory, the impairment of which is a core feature
of AD [47].
To date, results from RCTs are mostly nonsignificant,
with small effect sizes and little or no benefit of the MeDi
for incident cognitive impairment or dementia, as also
documented by a recent systematic review of RCTs by
Radd-Vagenas et al. [48]. RCTs with a longer duration
and higher number of participants are needed to establish
whether adherence to the MeDi can help prevent (or
delay) the onset of AD and dementia.
2.3. Mediterranean Diet and Brain Imaging.AD is a neurode-
generative disease characterized by typical changes in the
brain that can be detected by a variety of imaging modalities,
including structural and functional Magnetic Resonance
Imaging (MRI) and Positron Emission Tomography (PET).
In recent years, cross-sectional and longitudinal studies have
shown the relationship between lifestyle and dietary habits
and the morphological, structural, functional, and metabolic
modifications of the brain regions that undergo neurodegen-
eration in the preclinical and clinical phases of AD.
2.3.1. Mediterranean Diet and Structural Brain
Modifications. Growing evidence, derived mainly from MRI
studies, suggests an association between higher MeDi adher-
ence and preservation of brain structures, in particular in the
so-called “Regions-of-Interest” (ROIs) which are vulnerable
to the neurodegenerative changes typical of AD. Higher
MeDi adherence was associated with a significantly greater
thickness of 3 ROIs (orbitofrontal cortex, entorhinal cortex,
and posterior cingulate cortex of the left hemisphere) in a
cross-sectional study performed on an American population
of cognitively normal middle-aged participants [49]. Similar
findings were reported by two other cross-sectional
American studies in which the greatest benefit in terms
of brain structure preservation was attributed to the
higher intake of fish and legumes and lower intake of
meat [50, 51]. More recently, Karstens et al. found that
higher adherence to the Mediterranean pattern was asso-
ciated with better learning and memory performance and
larger bilateral dentate gyrus volumes after adjusting for a
number of confounding factors [52].
Conversely, several longitudinal studies reported a nega-
tive effect on brain structures related to lower adherence to
the MeDi [53] or adherence to an unhealthy Western dietary
pattern [54], while a Swedish longitudinal study including
194 cognitively healthy elderly individuals found no
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association between the total MeDi score and the brain
volumes perhaps due to the intrinsic limitations of the study
design [55].
In conclusion, gray matter atrophy and reduced cortical
thickness in the medial temporal lobe are a typical early fea-
ture of AD, and the association of MeDi adherence with
greater gray matter volumes in AD regions may indicate
some direct involvement of this type of dietary pattern in
preventing or slowing the neurodegeneration and the conse-
quent neuronal loss that is typical of this disease. More
recently, Pelletier and colleagues reported a positive associa-
tion between higher MeDi adherence and a general pattern of
preserved white matter microstructure with no relation to
gray matter volumes, suggestive of alternative mechanisms
partly independent of AD-related neurodegeneration, possi-
bly including vascular pathways [56]. The beneficial effect
of the MeDi on vascular risk factors (e.g., lipid profile, blood
pressure, insulin resistance, adiposity, inflammation, and
oxidative stress) is in fact well established [57–60].
2.3.2. Mediterranean Diet and Functional Brain
Modifications. The AD brain is characterized by several met-
abolic changes that can also be found in other neurodegener-
ative diseases and in normally aging brains and represent
nonspecific biomarkers of impairment of neuronal activity
and synaptic transmission. These metabolic and functional
modifications can be detected by PET, in particular, fluoro-
deoxyglucose- (FDG-) PET and Pittsburgh Compound B-
(PiB-) PET which allow us to evaluate changes in cerebral
glucose metabolism (an indicator of neuronal network activ-
ity) and the degree of beta-amyloid (Aβ) deposition in brain
regions known to be involved in AD. Studies concerning the
association between MeDi adherence (and in general, adher-
ence to a healthy dietary pattern) and functional neuroimag-
ing outcomes are limited.
Two cross-sectional studies in the American population
found an association between higher adherence to a MeDi
pattern and lower 11C-PiB PET scan measurements of Aβ
deposition as well as higher glucose metabolism as observed
by FDG-PET scans [61, 62]. HigherMeDi adherence was also
associated with reduced cerebral Aβ accumulation over time
(up to 3 years) in a longitudinal study performed by Rainey-
Smith et al. on older Australian adults classified as “Aβ accu-
mulators” and thus considered to be on the way to AD [63].
However, the association between the Mediterranean dietary
pattern and amyloid deposition or cortical thickness has not
been confirmed in all reported studies. In a longitudinal
study that involved 70 middle-aged participants living in
New York, lower adherence to a Mediterranean-style diet
was associated with faster decline in glucose metabolism in
the posterior cingulate cortex (an early site of cerebral glu-
cose utilization decline in AD and a well-established predic-
tor of the progression from mild cognitive impairment to
AD) and marginally in the frontal cortex, although without
any significant changes in amyloid deposition or cortical
thickness [64].
In conclusion, the neuroprotective effects of the MeDi
may also lie in its ability to preserve brain metabolic activity
and glucose metabolism in key brain regions for AD.
3. DASH Diet and AD Prevention
The DASH diet, which stands for Dietary Approaches to Stop
Hypertension, promoted by the National Heart, Lung, and
Blood Institute (NHLBI), is a dietary pattern that was first
developed to identify dietary factors affecting blood pressure.
The DASH diet is high in fruits, vegetables, nuts, whole-
cereal products, low-fat dairy products, fish, and poultry, all
of which are rich in blood pressure-deflating nutrients like
potassium, calcium, “lean proteins,” minerals, and fiber (see
Table 1). DASH also discourages the intake of foods like
red and processed meats, full-fat dairy foods, and tropical
oils, as well as sugar-sweetened beverages and sweets; there-
fore, it is designed to be low in sodium, saturated fats, total
fats, and cholesterol [65]. This type of dietary pattern has
been shown to protect against many cardiovascular risk fac-
tors that play a role in the development of dementia and
AD (such as high blood pressure or LDL cholesterol), at least
in part by modulating the pathological processes that charac-
terize the physiopathology of AD (oxidative stress, inflam-
mation, and insulin resistance) [66]. DASH and MeDi
share many food components (i.e., whole-grains, vegetables,
and nuts), but there are also some differences, such as the fre-
quency of consumption of low-fat dairy products (moderate-
to-high intake and low consumption, respectively).
To date, only a few studies have evaluated the potential
effects of the DASH diet on cognitive functions or on the pre-
vention of AD and other types of dementia.
3.1. Epidemiological Evidence. As already stated with regard
to the Mediterranean diet, higher adherence to the DASH
diet has been associated with slower rates of cognitive decline
and reduced incidence of AD [67–69] (see Table 2).
In the study of Morris and colleagues [68], only the high-
est tertiles of the DASH and MeDi scores were significantly
associated with a lower rate of incident AD (39% and 54%
reduction, respectively).
Berendsen et al. [69] found a positive association between
long-term adherence to the DASH diet and better cognitive
function in older American women participating in the
Nurses’ Health Study, regardless of apolipoprotein E ε4 allele
status, but not with slower cognitive decline during the
course of follow-up (6 years). On the contrary, another study
which included only older American women, the Women’s
Health Initiative Memory Study (WHIMS), reported that
DASH scores were not associated with incidence of MCI or
dementia [70].
3.2. RCTs. The only RCT which examined the potential
effects of the DASH diet on neurocognitive functioning was
performed some years ago by Smith and colleagues [71]
(see Table 2). In the ENCORE trial 124 subjects with high
blood pressure were randomized to the DASH diet alone or
DASH combined with a behavioral weight management pro-
gram including exercise and calorie restriction (CR), or to a
“usual diet” control group. After 4 months of intervention,
psychomotor function improved in both DASH interven-
tions regardless of weight strategies, but only the group
which underwent a combination of DASH diet with aerobic
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exercise and calorie restriction showed a significant improve-
ment in neurocognitive function (executive memory and
learning functions) [71].
4. MIND Diet and AD Prevention
The MIND diet (Mediterranean-DASH Intervention for
Neurodegenerative Delay) was developed some years ago by
researchers at Rush University Medical Center in Chicago,
IL, and Harvard School of Public Health in Boston, MA, as
a hybrid of the Mediterranean-DASH diet. The MIND diet
is based on 10 brain-healthy foods (leafy green vegetables,
other vegetables, nuts, berries, beans, whole grains, fish, poul-
try, olive oil, and wine) and 5 unhealthy foods (red meats,
butter and stick margarines, cheese, pastries and sweets,
and fried or fast food), all of which have a strong scientific
rationale in the field of nutritional prevention of dementia
[72, 73] (see Table 1). Compared to the MeDi, the MIND diet
includes a lower consumption of fish, usually 1 serving/week,
as does the DASH diet. This relatively low level of fish con-
sumption reflects the findings of prospective epidemiological
studies, such as the Rotterdam study which examined the role
of fish intake in AD prevention [74–76]. As stated above,
leafy green vegetables, in addition to other types of vegeta-
bles, are recommended on the basis of several epidemiologi-
cal studies that reported a significant association between
high consumption and slower cognitive decline [77, 78].
Berries represent a separate category in the MIND diet,
reflecting strong associations between the consumption of
this type of fruit and brain health. Many studies have docu-
mented the beneficial effects of various types of berries,
including potent anti-inflammatory and antioxidant activity
in cell models of neurotoxicity [79, 80]. Moreover, in vivo
studies on animals supplemented with a berry-enriched diet
reported improvements in motor coordination, cognitive
performance (spatial memory, learning), hippocampal
plasticity, and age-related neuronal loss [81–83]. A unique
characteristic of berries is the high content of polyphenols
such as flavonoids (anthocyanins and flavonols), which are
the main compounds responsible for the antioxidant and
anti-inflammatory characteristics of berries [84, 85]. The
association between a high intake of berries and flavonoids
and slower rates of cognitive decline have also been reported
in humans [86], confirming the results that were observed in
experimental studies.
4.1. Epidemiological Evidence. Two papers published by
Morris and other researchers from Rush University (Chi-
cago, IL, USA) clearly demonstrated the superiority of
the MIND diet compared to both the MeDi and the DASH
diet in slowing the rates of cognitive decline [28] and in
reducing the risk of incident AD or dementia [68]. The
MIND diet score was linearly and statistically significantly
associated with a lower risk of developing AD (see Table 2).
Subjects in both the middle and the highest tertiles of MIND
scores had a statistically significant reduction in AD rates
compared to those in the lowest tertile, while only those
in the highest tertile of MeDi and DASH scores were sig-
nificantly associated with a lower rate of incident AD [68].
To date, no randomized controlled trials have been pub-
lished evaluating the effect of the MIND diet on the pre-
vention of AD, but there are two ongoing studies testing
the effects of an intervention with the MIND diet on cog-
nitive decline and brain neurodegeneration, the results of
which will be reported in the coming years (http://www
.clinicaltrials.gov/NCT02817074, http://www.clinicaltrials.gov/
NCT03585907).
5. Dietary Patterns and the Brain: The
Underlying Mechanisms
The clinical evidence that has been collected in recent years
suggests that the dietary patterns described above, namely,
the Mediterranean diet, the DASH diet, and more recently
the MIND diet, are able to modify the natural history of
neurodegenerative pathologies, in particular AD, thereby
preventing their development or slowing down their progres-
sion. But what is the basis of the favorable neuroprotective
effects of these dietary patterns? What are the links between
diet and the human brain? Are there any other factors that
modulate the effects of diet on the brain?
The strength of these dietary approaches lies in their
multifactorial composition. In fact, nutrient-dense foods
can interact with each other with potentially synergistic
effects on different metabolic and cellular signaling path-
ways, leading to neuroprotection and maintaining brain
health. But there are considerable methodological difficul-
ties in conducting in vitro and in vivo studies to document
the effects of such dietary patterns on the brain, due to the
intrinsic complexity of a whole diet, the micro- and macro-
nutrient composition, the importance of food cooking
methods, and at least for the Mediterranean diet, the unde-
niable aspect of conviviality that characterizes this dietary
lifestyle. All of these aspects are obviously difficult to repro-
duce and quantify in experimental models.
To date, the precise mechanisms underlying the neuro-
protective benefits associated with the MeDi and the other
dietary patterns are not fully understood, even if it is
widely accepted that they play a role in counteracting sev-
eral biological processes implicated in the pathogenesis of
AD, e.g., oxidative stress, neuroinflammation, neurovascu-
lar dysfunctions and hypoperfusion, disruption of the gut-
brain axis, and impairment of hippocampal neurogenesis.
It is also possible that these dietary patterns might influ-
ence Aβ or Tau metabolism, even if evidence concerning
these mechanisms were largely obtained from animal studies
and require further assessment and confirmation [87, 88]. At
a systemic level, they can also indirectly improve cognition by
reducing cardiovascular risk factors such as lipid levels, blood
glucose, and blood pressure [89, 90].
5.1. Neurovascular Dysfunctions. Cerebral blood flow regula-
tion is essential for normal brain function. AD is known to be
associated with early neurovascular dysfunction and damage
to small arteries, arterioles, and brain capillaries via both Aβ-
independent (such as hypoxia and/or ischemia) and Aβ-
dependent pathways (Aβ angiopathy). These changes,
together with the loss of integrity of the blood-brain barrier
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(BBB), play a part in disease pathogenesis and lead to neuro-
nal and synaptic dysfunction, neurodegeneration, and cogni-
tive impairment [91, 92]. Several risk factors can contribute
to neurovascular dysfunction, for example, genetic factors
(APOE4 genotype), vascular factors (hypertension and
diabetes mellitus), and environmental factors (for example,
pollution). Hypertension is a well-known risk factor for
AD, and animal studies have shown impairment in
acetylcholine-dependent and endothelium-dependent vaso-
dilation with a consequent reduction of cerebral blood flow
after several stimuli [93]. Chronically elevated blood pressure
can also enhance Aβ-induced neurovascular dysfunction,
promote β-secretase activity, and lead to amyloidogenic pro-
cessing of the amyloid precursor protein (APP), with further
damage to small arteries and arterioles, rupture of the vessel
wall, and microhemorrhages [93].
Hence, the importance and the possible preventive and
neuroprotective role of a diet such as the DASH diet, which
thanks to its reduced content of sugars, sweets/pastries, and
sodium can act positively on some of the triggers of neuro-
vascular dysregulation (hypertension and hyperglycemia/in-
sulin resistance) [94]. In addition to limiting the intake of
such detrimental foods and nutrients, increasing evidence
supports the regular consumption of flavonoid-rich foods,
which are associated with better endothelial function, tissue
perfusion, and enhanced neuronal viability. For example,
the flavonoids contained in cocoa powder (mainly epicate-
chin) act directly on the endothelium of brain vessels
enhancing the activity of endothelial nitric oxide synthase
(eNOS) and thereby increasing vasodilatation and cerebro-
vascular perfusion [95].
5.2. Oxidative Stress. The imbalance between the production
of reactive oxygen species (ROS) and antioxidant defenses
has been shown to contribute significantly to the pathogene-
sis and progression of AD [96] and is known to be associated
with oxidative damage to DNA, proteins, and lipidic compo-
nents of neurons and with subsequently impaired synaptic
activity and neuronal apoptotic death [96]. Several antioxi-
dant compounds can modulate signaling cascades involving
protein and lipid kinases and downstream partners, resulting
in the inhibition of neuronal apoptosis induced by toxic
products such as ROS [97].
All three dietary patterns discussed in this review are
exceptionally rich in foods with a high antioxidant content.
Leafy green vegetables and other vegetables, citrus fruits,
nuts, red wine, berries, and olive oil all provide a large
amount of vitamins, polyphenols, and carotenoids that can
prevent and/or repair the damage caused by free radicals
(e.g., superoxide, O2
⋅− and nitric oxide, NO⋅) and by proin-
flammatory cytokines (e.g., IL-1β and TNF-α) that are pro-
duced by activated microglial cells in response to oxidative
damage. One of the main components of the Mediterranean
diet, as well as the main source of fat in this diet, is extravirgin
olive oil (EVOO), which contains mainly oleic acid and to a
lesser extent linoleic acid. In addition, EVOO contains hun-
dreds of bioactive compounds including triterpenes (i.e.,
squalene), biophenols (hydroxytyrosol, tyrosol, and oleuro-
pein), pigments (carotenoids, xanthophylls, and lutein), and
vitamin E (tocopherols), whose beneficial effects have been
shown in several studies [98, 99]. The low (and nontoxic)
level of oxidized forms of EVOO polyphenols in plasma
and tissues can activate the Nrf2 pathway and other adaptive
stress response systems leading to the upregulation of the
endogenous antioxidant and detoxification enzymes and
thus rendering the cells “protected” against more dangerous
and chronic oxidative stress stimuli (hormesis) [100]. Recent
studies have shown that hydroxytyrosol, oleuropein, and
oleacein can activate the Nrf2 pathway both in vitro and
in vivo [101, 102].
5.3. Neuroinflammation. Microglial cells are the first and
most important immune defense of the brain. While proper
microglial function is essentially required for scavenging pla-
ques, damaged molecules, and infectious agents, microglial
hyperactivation is a well-established hallmark of neuroin-
flammation and one of the main actors in AD pathogenesis
[103]. In the AD process, the excessive production and
deposition of the Aβ peptides trigger an innate immune
response and consequently an aberrant production of
ROS, proinflammatory cytokine, and chemokine secretion,
and degradation of the neuroprotective factors, such as
retinoids, involved in promoting adult neurogenesis in
the hippocampus [104, 105]. This chronic inflammatory
response contributes to disease progression and severity,
further boosts Aβ production and deposition, and ultimately
leads to neuronal death [106, 107]. Several exogenous or
endogenous factors can exacerbate the innate immune
response mounted by Aβ-exposed microglia, including
genetic factors (for example, TREM2 mutation [108] and
APOE4 genotype [109]), traumatic brain injuries, diabetes
[110], and obesity [111]. Diet is known to modulate the
immune system, and a healthy diet rich in nutrients and bio-
active compounds with anti-inflammatory and antioxidant
properties can help to counteract the neuroinflammatory
process.
Fruits, vegetables, whole grains, and other plant foods
provide a wide range of phytochemicals, vitamins, min-
erals, and fibers with well-established antioxidant anti-
inflammatory properties. Phytochemicals are bioactive
plant-derived compounds that include various subgroups
(phenolics, alkaloids, organosulfur compounds, phytos-
terols, and carotenoids). One example is Ferulic Acid
(FA), an antioxidant with free radical scavenging activity
but also antiamyloidogenic properties, as documented in a
number of in vitro [112, 113] and in vivo studies [114, 115]
in transgenic mouse models of AD. Resveratrol, another phe-
nolic compound, is mainly found in the skin of many edible
plant species, such as mulberries, grapes, peanuts, and pome-
granates, as well as in red wine [116]. There are a multitude of
actions that have been attributed to resveratrol: inhibition of
Tau and Aβ plaque synthesis [117, 118], downregulation of
prooxidative stress proteins [119] and increased levels of
heme-oxygenase-1 (HO-1) [120] and SIRT-1, and inhibition
of neuroinflammation [121, 122].
Long chain omega-3 polyunsaturated fatty acids (n − 3
PUFAs) are also important [123]. Docosahexaenoic acid
(DHA) and Eicosapentaenoic Acid (EPA), two main types
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of n − 3 PUFAs, are abundantly present in seafood and fish
oil. In vitro experiments showed that EPA and/or DHA
administration decreases the expression of proinflammatory
factors, such as inducible NO synthase (iNOS), cyclooxygen-
ase (COX) 2, interleukin-1β (IL-1β), IL-6, Tumor Necrosis
Factor-α (TNF-α), and Nuclear Factor-κB (NF-κB), and pro-
motes the expression of anti-inflammatory cytokines. In
rodents, the consumption of a diet enriched in n − 3 PUFAs
prevents the dysregulation of cytokine production in hippo-
campal microglial cells in response to Lipopolysaccharide
(LPS) [124], reduces hippocampal Aβ plaque density by
modifying the fibrillar/prefibrillar Aβ oligomer ratio (the for-
mer are less toxic), and leads to mild improvements in the
behavioral testing of the transgenic APP/PS1 rodent model
of AD [125]. Moreover, dietary omega-3 and omega-6 PUFA
and monounsaturated fatty acid (MUFA) intake may influ-
ence the membrane fluidity and enzyme activity in neurons,
leading to the potential modulation of brain structures and
functions [126].
5.4. Gut Microbiota Dysbiosis. The human gut microbiota
includes approximately 1014 microbes belonging to hundreds
different species and to five predominant phyla and is mainly
composed of two phyla: Firmicutes (60-80%) and Bacteroides
(20-30%), followed by Actinobacteria, Verrucomicrobia, and
Proteobacteria [127, 128]. The gut microbiota plays a crucial
role in human health but also in a variety of human diseases,
at least in part through the production and release of numer-
ous small molecules like vitamins (folate, vitamin B12),
amino acids (tryptophan), and short chain fatty acids
(SCFAs). Some of these bioactive substances (SCFAs,
catecholamines, neurotransmitters, neuropeptides, and miR-
NAs) are transported into the blood and can cross the BBB
thus affecting the central nervous system (CNS). Addition-
ally, the CNS communicates with the gut through efferent
autonomic pathways, thus modulating many gut functions
like permeability, mucus secretion, motility, and immunity.
This bidirectional communication between the gastrointesti-
nal system and the CNS is called the gut-brain axis [129].
A healthy microbiota is fundamental for the metaboliza-
tion of such dietary nutrients (like polyphenols) which
require transformation to become active compounds having
beneficial effects on the brain. Curcumin metabolites pro-
duced by the microbiota can exert anti-inflammatory and
neuroprotective effects [130], including interesting positive
effects on Tau pathology [131].
The composition of human gut microbiota is dynamic
and can be shaped by various factors such as the type of
childbirth and newborn feeding, diet, use of drugs, or pre/-
probiotics, as well as age, sex, and geographical area. The
Mediterranean diet, which is rich in plant-based foods, fibers,
and monounsaturated fats, is considered the gold standard
for gut health and promotes the diversification of the micro-
biota [132]. Conversely, the typical Western diet, which is
made up of low dietary fiber and high animal protein and sat-
urated fat, is associated with a negative change in the gut
microbiota composition (dysbiosis), as documented by an
increase in Firmicutes and Gram-negative bacteria [133].
As previously mentioned, age is another important modulat-
ing factor of human gut microbiota composition. Several
reviews analyzed gut microbiota age-related changes and
the potential relationships between gut dysbiosis and inflam-
maging [134–136].
During aging, the gut undergoes a continuous and
profound remodeling, as a result of modification of lifestyle,
nutrition, behavior, immunosenescence (a decline in an
immune system functioning), and inflammaging (the
chronic low-grade inflammatory status typical of the elderly).
Moreover, aging-associated alterations in gut physiology (i.e.,
gastric motility disorders, hypochlorhydria, and degenerative
changes in the enteric nervous system) have profound effects
on the diversity, composition, and functional features of
intestinal microbiome [137]. Several authors reported a
reduction in the microbiota diversity and a greater interindi-
vidual variation in microbiota composition in elderly people
(>65 years of age), with reduced numbers of Bifidobacteria,
Firmicutes, Faecalibacterium prausnitzii, and Clostridium
cluster XIV and increased numbers of Bacteroidetes and
Enterobacteriaceae even if with some differences between
various populations [138–140].
The inflammatory process can affect the gut environment
by enhancing the level of aerobiosis and the production of
ROS that inactivate the strict anaerobic Firmicutes, while
allowing the growth of facultative aerobes (i.e., Enterobacteri-
aceae, Enterococcaceae, and Staphylococcaceae). These so-
called “pathobionts” can survive in the presence of oxygen,
so they can prosper in an inflamed gut, and in turn, they pro-
mote a proinflammatory profile (increase of Il-6 and Il-8
levels) and compromise the host immune homeostasis, in a
sort of self-sustaining loop [141].
Gut dysbiosis has been linked to the development of
several health problems, including psychiatric or neurode-
generative diseases. An increasing body of evidence sug-
gests that alterations to the gut microbiota can play a
role in the pathogenesis of AD. Dysbiosis can amplify neu-
roinflammation and accelerate neurodegeneration, and this
brain-gut microbiota axis can actually be modulated by
dietary factors. In aging mice, AD-like symptoms were
associated with increased gut permeability, inflammation,
and a microbiome profile similar to that of murine inflam-
matory bowel disease [142]. Experimental mice models of
AD showed a decrease in microbiota diversity with age,
an increased number of taxa with proinflammatory activity
(e.g., Odoribacter, Helicobacter, and Sutterella), and
impaired production of SCFAs [143, 144]. All these mod-
ifications can be worsened by feeding transgenic mice a
high-fat diet [145]. Moreover, gut microbiota dysbiosis in
mouse models of dementia may be involved in neuroin-
flammation, reduced expression of hippocampal brain-
derived neurotrophic factor (BDNF) and other signaling
molecules, and amyloid deposition [146–148]. Conversely,
administering probiotics to rodents with artificially
induced AD led to an improvement in cognitive functions,
especially spatial working tasks, less neuron degeneration
and lower levels of proinflammatory cytokines [149–151],
microglial activation and oxidative stress, improved mito-
chondrial dysfunction, and restoration of hippocampal
plasticity [152].
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In conclusion, long-term dietary habits may influence gut
microbiota biodiversity, its functions, and the secretion of
metabolites that, once absorbed in the systemic circulation,
can modulate neural function and possibly enhance neuroin-
flammation, neuronal apoptosis, and β-amyloid deposition
[153]. The modulation of gut microbiota by adopting and
maintaining a healthy diet can be an effective strategy in
AD prevention. However, the transposition of these results
into humans is still premature given the absence of clinical
studies, especially in middle-aged or older patients at risk of
developing AD or with MCI.
5.5. Adult Hippocampal Neurogenesis. The hippocampus is
the key brain region for learning and memory. Incorporation
of new neurons into the granular cell layer of the dentate
gyrus of the hippocampus is substantial throughout life,
and adult neurogenesis has important implications in main-
taining cognitive functions [154]. This brain area is highly
involved in the process of neurodegeneration that is typical
of AD. Numerous studies have documented an impairment
of neurogenesis and relative memory loss as well as cognitive
dysfunction in mouse models of AD even in the very early
stages of the disease [155]. Environmental factors such as
exercise and calorie restriction (see the specific chapter
below) have been shown to increase adult hippocampal neu-
rogenesis, while low-grade inflammation and oxidative stress
seem to decrease it [156]. Hippocampal neurogenesis is reg-
ulated by several signaling pathways such as presenilin-1,
Notch 1, soluble amyloid precursor protein, CREB, and β-
catenin and is also mediated by neurotrophins such as
BDNF. A poor diet can have detrimental effects on hippo-
campal neurogenesis. Diets that are rich in saturated fat-
s/trans fatty acids and refined sugars, like Western diets,
reduce the levels of BDNF and contribute to an increased
production of ROS and proinflammatory cytokines, leading
to neurodegeneration and learning and memory impairment
[157]. On the contrary, dietary patterns based on foods that
are rich in omega-3 fatty acids, flavonoids, and other antiox-
idants stimulate neurogenesis, reduce oxidative activity, and
downregulate proinflammatory processes [158, 159].
6. Intermittent Fasting: A New Dietary
Pattern for AD?
Aging is one of the main risk factors for AD. The aging brain
and the “AD-Brain” share many characteristics, both at an
anatomical and at a cellular/molecular level [160]. Indeed,
many of the principal hallmarks of aging (e.g., oxidative
stress, mitochondrial dysfunction, accumulation of oxida-
tively damaged molecules, impaired autophagy, disruption
of Ca2+ homeostasis, aberrant neuronal network excitability,
and neuroinflammation) have also been documented in AD,
and these changes may promote amyloidogenic APP pro-
cessing and Tau pathology and vice versa [161, 162].
Over the last 30 years, emerging evidence has shown the
beneficial effects of fasting and CR as alternative or comple-
mentary strategies to other lifestyle interventions (e.g., phys-
ical activity) and to pharmacological therapies in AD
prevention and treatment.
During the first 10-14 hours of fasting, the main source of
energy for neurons is made up of glucose derived from the
degradation of the liver glycogen store. Then, a “metabolic
switch” occurs, characterized by liver production of Ketone
Bodies (KBs) like β-hydroxybutyrate (BHB) and acetoacetate
(AcAc) from the fatty acids released by adipose tissue in
response to fasting; in this second phase, KBs represent the
main fuel for neurons [163]. Besides this “metabolic switch,”
fasting can enhance a complex series of adaptive responses to
limited food availability, which are to some degree, the same
endogenous stress-response systems activated by foods that
are rich in polyphenols and other bioactive compounds (as
described above) [164].
In prokaryotes, laboratory animals and humans, a daily
20-40% CR, can protect against aging, oxidative stress, and
neurodegenerative disorders and can also extend longevity
[165, 166], but the feasibility and long-term tolerability are
low, especially in patients with AD. Other studies have shown
the same positive results by alternating normal diets with
more feasible regimens, such as intermittent fasting (IF) or
periodic fasting (PF) that are short periods of fasting which
differ from each other with regard to duration and frequency.
The best-characterized form of fasting that has been studied
both in animal models and in humans is Alternate-Day Fast-
ing (ADF), which implies fasting every other day [167, 168]
or a 70% CR every other day [169, 170] or even 2 consecutive
days of Very Low-Calorie Diet (VLCD) per week [171].
Upcoming alternatives are the so-called Fasting-Mimicking
Diets (FMDs), characterized by periodic cycles of plant-
based dietary programs lasting from 3 to 7 days, that are
low in protein and in overall caloric intake but contain all
the necessary micronutrients [172, 173]. Regardless of how
fasting has been applied in these studies, it should be empha-
sized that it is different from starvation, which leads to
chronic insufficiency of nutrients, malnutrition, and ulti-
mately degeneration and death.
6.1. Why Is Fasting Good for the Brain?
6.1.1. Looking Briefly at the Molecular Mechanisms. Fasting
substantially modifies the neurochemistry and the activity
of the neuronal network especially in several brain regions
such as the hippocampus, the striatum, the hypothalamus,
and the brainstem. At the molecular level, a variety of signal-
ing pathways have been identified that mediate the structural
(increased synaptic density, neurogenesis) and functional
(Long-Term Potentiation, LTP) adaptive responses of neuro-
nal circuits to nutrient restriction, in particular low glucose
and amino acid levels [174] (see Figure 1). Both increased
excitatory synaptic activity and neurotrophic factors (BDNF
and fibroblast growth factor 2) lead to the activation of
multiple kinases, including phosphatidylinositol 3-kinase
(PI-3K), serine/threonine-protein kinase (AKT), Mitogen-
Activated Protein Kinases (MAPKs) and Ca2+/calmodulin-
dependent kinase (CaMK), nitric oxide synthase (NOS),
and calcineurin, which all converge on several transcription
factors like cAMP-Responsive Element-Binding protein
(CREB), nuclear regulatory factor 2 (Nrf2), and NF-κB
[166, 175]. These transcription factors, which include BDNF
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[166], sirtuin-3 (SIRT3) [176], peroxisome proliferator-
activated receptor γ coactivator 1α (PGC1α) [177], and
heat-shock protein 70 (HSP-70), induce the expression of
genes and proteins involved in enhancing neuroplasticity
and stress resistance [178]. Part of the benefits of CR/fasting
seems to be related to protein restriction and reduced
IGF1/insulin signaling. During protein restriction, mTOR,
and in particular complex 1 (mTORC1), is repressed, thus
allowing the cell to enter a “conservative” energy mode to
inhibit protein and lipid synthesis and enhanced autophagy
[179, 180].
6.2. Fasting and AD
6.2.1. Preclinical Studies. Most of the scientific evidence
regarding IF or PF regimens and AD treatment derives
from studies on laboratory animals. In rodents, several
studies showed that fasting and FMDs are able to improve
motor and cognitive functions, in particular hippocampal-
dependent tasks like learning and memory [172, 181–183].
Moreover, IF has been associated with reduced oxidative
stress and brain structural improvements such as increased
thickness of the CA1 pyramidal cell layer and higher
expression of the dendritic protein drebrin in the hippo-
campus [184].
IF and ketogenic diets can also modify neuronal network
activity and synaptic plasticity. The neurons of rodents on an
ADF regimen are more resistant to excitotoxin-induced
degeneration of hippocampal neurons with kainic acid and
perform better in water-maze learning and memory tasks
[167, 185]. IF and/or regular physical activity can also pre-
vent age-related deficits in LTP, a common cellular manifes-
tation of learning and memory occurring in response to
repetitive stimulation of synapses [186–189]. Other research
groups also documented a role of CR/IF regimens in reduc-
ing Aβ deposition and Tau phosphorylation in the hippo-
campus and cerebral cortex of a transgenic mouse model of
AD [190–194]. Recently, Zhang et al. highlighted the role of
IF (and in particular BHB) in restoring the polarity of
AQP4, a protein channel involved in Aβ clearance, that is
often impaired in AD, thereby providing another possible
explanation for the positive role of ADF in improving cogni-
tive functions and protecting against Aβ pathology [195].
Lastly, IF, with or without exercise, stimulates the
growth and differentiation of new neurons into granule
neurons in the hippocampal dentate gyrus, i.e., adult hip-
pocampal neurogenesis, and the creation of synaptic con-
nections (dendritic spine growth and synaptogenesis)
among themselves or with other neurons from other brain
regions such as the entorhinal cortex, basal forebrain, and
amygdala [172, 196, 197].
6.2.2. CR and IF in Humans. Several human studies have
shown that the decrease in energy intake can reduce visceral
fat (while preserving lean mass), improve glucose and lipid
metabolism, and reduce blood pressure and blood bio-
markers of inflammation (C-reactive protein and proinflam-
matory cytokines) [171, 198, 199]. All these beneficial effects
may translate into a lower risk of cardiovascular disease, dia-
betes, and also neurodegenerative diseases such as AD.
Currently, no studies have been conducted on protein
and/or calorie restriction in human subjects with established
AD, but some authors have underlined the potential role of
protein restriction against the aging process and aging-
related chronic diseases [200]. However, it is important to
properly time the application of protein restriction during
life since the beneficial effects seem to be lost in people over
65 years of age [201].
Inflammation
Modulation of the
immune system
DNA repair
(APE-1)
Oxidative stress
balance (SOD2)
Synaptic plasticity
(PGC1훼, BDNF)
Autophagy
(↓mTOR)
Neurogenesis
(BDNF)
Mitochondrial
biogenesis
Calorie restriction
Intermittent fasting
Chronic overeating
Overweight/obesity
Insulin resistance
Figure 1: Signaling pathways involved in adaptive responses of neuronal circuits that contribute to maintain a healthy brain. Calorie
restriction and intermittent fasting positively modulate these pathways, while chronic overfeeding and insulin resistance enhance
neuroinflammation, neuronal damage, and apoptosis.
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Short periods of CR are able to improve cognitive func-
tion (verbal memory) in elderly subjects [202], and 30 days
of a low glycemic diet in patients with MCI resulted in an
improvement in delayed visual memory, cerebrospinal fluid
biomarkers of Aβ metabolism, and brain bioenergetics
[203], but it is hard to believe that severe restrictions could
be tolerated for long periods, especially in elderly subjects
affected by neurodegenerative diseases. IF regimens or
FMD cycles every 1-2 months seem to be more feasible and
tolerable in clinical practice. Recent pilot clinical trials apply-
ing such dietary regimens in healthy subjects and in patients
with cancer, diabetes, and multiple sclerosis have been devel-
oped and have shown promising results [172, 173, 204],
while several trials are still ongoing (https://clinicaltrials
.gov/NCT03595540, https://clinicaltrials.gov/NCT03700437,
and https://clinicaltrials.gov/NCT03811587).
The next step will be to demonstrate whether the various
types of fasting (including ADF and FMD) have neuropro-
tective and regenerative effects in patients with early-stage
AD. Our group will carry out a pilot study in an effort to
assess the safety and feasibility of monthly cycles of an
FMD diet in patients with a diagnosis of MCI or early AD.
In conclusion, emerging evidence on the effects of fasting
on animal models of aging brain and neurodegenerative dis-
eases is promising, but the applicability and potential efficacy
of these dietary regimens in humans, and in particular in
patients with MCI or AD, are yet to be established.
7. Conclusions
To date, it is not possible to establish with certainty a causal
relationship between diet and the development of AD
because there are still many confounding factors and biases:
(1) There may be confounding factors that contribute to
increasing or reducing the risk of AD (physical activ-
ity, cardiovascular risk factors, and apoE4 status)
(2) There is broad heterogeneity among the characteris-
tics of the studies, such as the mean age of the study
subjects (50-85 years), diverse geographic settings
(differences in the dietary patterns or in the environ-
mental factors in Mediterranean or non-
Mediterranean regions), sample size, study designs
(cross-sectional, prospective, case-control, and
RCTs), and length of follow-up
(3) Several different methods have been used for evaluat-
ing eating habits (different questionnaires, food
diary, and 24-hour dietary recall)
(4) There is broad heterogeneity in the criteria used for
the evaluation of cognitive performance and diagno-
sis of AD (single neuropsychological tests or neuro-
psychological batteries)
(5) None of the studies take into account the possible
modifications in an individual’s eating habits over
the course of one’s life as related to psychological
(e.g., depression), physiological (e.g., difficulty in
chewing and modification of appetite), or socioeco-
nomic changes (e.g., social isolation, financial diffi-
culties, and lack of family support)
(6) There is broad heterogeneity in the study outcomes
(AD incidence or prevalence, worsening of the over-
all cognitive performance or even of some specific
cognitive domains)
Currently available drugs (cholinesterase inhibitors and
memantine) are able to partially control the symptoms but
do not slow down the progression of AD. Therefore, there
is an urgent need for new complementary therapeutic
approaches, and in this context, the modulation of dietary
habits and well-conducted nutritional interventions could
be a useful and inexpensive tool.
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